Home › Companies › CGEM

Pipeline (10 active programs)

Discontinued (7)

• CLN-978 — B-Cell Non-Hodgkin Lymphoma · development of CLN-978 in relapsed/refractory B-NHL was discontinued in early 2024
• CLN-619 — Endometrial Cancer · discontinuation of further development of CLN-619 in patients with gynecological cancers as preliminary results did not meet internal threshold for advancement
• CLN-619 — Cervical Cancer · discontinuation of further development of CLN-619 in patients with gynecological cancers as preliminary results did not meet internal threshold for advancement
• CLN-619 — Non-Small Cell Lung Cancer · In November 2025, after a review of the emerging clinical data in patients with NSCLC and multiple myeloma, we discontinued further development of CLN-619.
• CLN-619 — Multiple Myeloma · In November 2025, after a review of the emerging clinical data in patients with NSCLC and multiple myeloma, we discontinued further development of CLN-619.
• CLN-617 — undisclosed · In November 2025, after a review of the emerging clinical data in patients with advanced solid tumors, we discontinued further development of CLN-617.
• CLN-418 — undisclosed · discontinued development of CLN-418 and returned development and commercial rights for CLN-418 to Harbour

Biotech Distilled coverage (7)

• 2026-06-10 UPDATE: Cullinan Therapeutics (CGEM) - The Second Leg Lands
• 2026-06-08 UPDATE: Cullinan Therapeutics (CGEM) - The Full Poster Lands, the Stock Sells the News
• 2026-05-19 UPDATE: Cullinan Therapeutics (CGEM) - The Abstract Drop Front-Runs EULAR 🔒 Paid
• 2026-05-08 UPDATE: Cullinan Therapeutics (CGEM) - The Catalyst Has a Date and a Stage 🔒 Paid
• 2026-04-29 UPDATE: Cullinan Therapeutics (CGEM) - The PDUFA Lands, the ATM Opens 🔒 Paid
• 2026-03-14 UPDATE: Cullinan Therapeutics (CGEM) - A 14% Haircut on Housekeeping Filings 🔒 Paid
• 2026-01-22 Cullinan Therapeutics (CGEM): Scientific Deep Dive for CLN-978 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.